Epigenetic agents in combined anticancer therapy.

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Epigenetic drugs, including DNA methyltransferase and histone deacetylase inhibitors, are established cancer therapeutics.
• These agents demonstrate significant anticancer effects and acceptable side effect profiles.
• However, their efficacy is limited in certain cancer types and phenotypes.

Purpose of the Study:

• To review the combined application of epigenetic agents with other cancer therapies.
• To discuss the general principles and supporting evidence for combination strategies.
• To predict future applications of this therapeutic approach.

Main Methods:

• Literature review of studies on combined epigenetic therapy.
• Summarization of general principles and examples of combined applications.
• Analysis of future potential of combination methodologies.

Main Results:

• Epigenetic drugs are effective but not in all cancers.
• Combination therapies enhance drug efficacy, overcoming limitations.
• Examples include combinations with chemotherapy, radiation, immunotherapy, oncolytic virotherapy, and hyperthermia.

Conclusions:

• Combined application of epigenetic agents with other modalities is a promising strategy to improve cancer treatment.
• This approach addresses limitations of monotherapy and broadens therapeutic potential.
• Future research should focus on optimizing these combinations for diverse cancers.